Torch

Professor Anthony Maraveyas

Professor in Cancer Medicine

Faculty and Department

  • Faculty of Health Sciences
  • Hull York Medical School

Summary

I graduated from Athens Medical School in 1983 and completed internal medicine training in 1990. In 1995 I was awarded my PhD from the University of London on monoclonal antibodies in Head and Neck Cancer. I completed my cancer specialty training as a lecturer at St George's hospital studying the immunology of melanoma cell vaccine therapeutics. I was appointed as a Senior Lecturer at the University of Hull in 1999 part of the founding team of Hull York Medical School, where I became professor of Cancer Medicine in 2012.

I am also a honorary consultant in the Hull University Teaching Hospitals NHS Trust (HUTH) having also been the Director of R&D till 2021. I treat and am involved in clinical trials in pancreaticobiliary, kidney cancer and melanoma and have particular clinical and basic science research interest in cancer associated thrombosis (CAT).

I have been national and international chief investigator for a number of studies in CAT and have worked on international guideline bodies for this condition. I have published widely in CAT with particular focus on the thromboprophylaxis of the ambulatory cancer patient and the management of incidental pulmonary embolism in cancer patients.

Recent outputs

View more outputs

Journal Article

Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series

Brown, M., O’Connor, D., Turkington, R., Eatock, M., Vince, R., Hulme, C., …Prue, G. (2023). Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series. BMC Sports Science, Medicine and Rehabilitation, 15(1), Article 116. https://doi.org/10.1186/s13102-023-00722-3

Abstract A020: Calcitonin receptor-like receptor is expressed in blood vessels in clear cell renal cell carcinoma and upregulated in endothelial cells co-cultured with tumor cells

Morfitt, M. A., Greenman, J., Maraveyas, A., Harris, A. L., & Nikitenko, L. L. (2023). Abstract A020: Calcitonin receptor-like receptor is expressed in blood vessels in clear cell renal cell carcinoma and upregulated in endothelial cells co-cultured with tumor cells. Cancer Research, 83(16_Supplement), A020-A020. https://doi.org/10.1158/1538-7445.kidney23-a020

Abstract B001: Calcitonin receptor-like receptor agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated human blood endothelial cells after bevacizumab treatment

Morfitt, M. A., Greenman, J., Maraveyas, A., & Nikitenko, L. L. (2023). Abstract B001: Calcitonin receptor-like receptor agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated human blood endothelial cells after bevacizumab treatment. Cancer Research, 83(16_Supplement), B001-B001. https://doi.org/10.1158/1538-7445.kidney23-b001

Quantitative proteomics of pancreatic cyst fluid for early diagnosis of cancer.

Nikitenko, L. L., Manolis, D., O'Brien, D. P., Adekeye, A., Kessler, B. M., Collins, C., …Maraveyas, A. (2023). Quantitative proteomics of pancreatic cyst fluid for early diagnosis of cancer. Pancreatology, 23(4), e7-e8. https://doi.org/10.1016/j.pan.2023.04.025

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool

Goedegebuur, J., Abbel, D., Accassat, S., Achterberg, W. P., Akbari, A., Arfuch, V. M., …Noble, S. I. (2023). Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool. Thrombosis Research, 228, 54-60. https://doi.org/10.1016/j.thromres.2023.05.008

Lead investigator

Project

Funder

Grant

Started

Status

Project

Differentiating the malignant potential of pancreatic cysts

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£293,225.00

Started

1 October 2017

Status

Complete

Project

TEM-PAC 2: Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions - Maraveyas

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£89,343.00

Started

1 January 2023

Status

Complete

Co-investigator

Project

Funder

Grant

Started

Status

Project

TRANSFORM: Reducing Inequalities in Cancer Outcomes in Yorkshire: Realising our potential for innovation in Diagnosis, Patient Management, Survivorship and Palliative Care Research

Funder

YCR Yorkshire Cancer Research

Grant

£1,806,650.00

Started

1 September 2017

Status

Ongoing

Project

Consumables for PhD project Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions (TEM-PAC)

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£22,980.00

Started

1 February 2021

Status

Ongoing

Project

SERENITY: Towards cancer patient empowerment for optimal use of antithrombotic therapy at the end of life

Funder

UKRI UK Research and Innovation

Grant

£198,784.00

Started

1 October 2022

Status

Ongoing

Project

EARLY DIAPAC: EARLY DIAgnosis of PAncreatic Cancer by combined proteomics and genomics testing of pancreatic cyst fluid.

Funder

CRUK Cancer Research UK

Grant

£72,818.00

Started

1 December 2022

Status

Ongoing

Project

ACF 2023-2026

Funder

NIHR National Institute for Health Research

Grant

£85,576.00

Started

1 September 2023

Status

Ongoing

Project

EARLY DIAPAC: EARLY DIAgnosis of PAncreatic Cancer by combined proteomics and genomics testing of pancreatic cyst fluid.

Funder

Cancer Research Technology Ltd

Grant

£33,551.00

Started

1 November 2023

Status

Ongoing

Project

A study of the incorporation and release of tissue factor as cancer cell-derived microparticles.

Funder

YCR Yorkshire Cancer Research

Grant

£163,682.00

Started

1 August 2014

Status

Complete

Project

Can prevention of the activation of PAR2 prevent the release of procoagulant microvesicles from cancer cells, reduce the risk of VTE and contain the deterioration of the vasculature?

Funder

Bristol Myers Squibb

Grant

£56,000.00

Started

1 July 2015

Status

Complete

Project

Molecular pathways of pancreatic cancer carcinogenesis from pancreatic cystic neoplasms to adenocarcinoma

Funder

NIHR National Institute for Health Research

Grant

£0.00

Started

1 September 2020

Status

Complete

Project

Quantitative proteomic analysis of pancreatic cyst fluid for early detection of cancer using University of Hull HPC Viper

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£6,000.00

Started

1 April 2022

Status

Complete

Project

TEM-PAC 2: Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions - Nikitenko

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£65,651.00

Started

1 January 2023

Status

Complete

Project

TEM-PAC 2: Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions - Ettelaie

Funder

Hull University Teaching Hospitals NHS Trust

Grant

£57,691.00

Started

1 January 2023

Status

Complete

Postgraduate supervision

Currently 4 PhD students:

Matthew Morfitt

Farzana Haque

Shirin Hasan

Saeed Alqarni

Recently awarded:

Sophie Featherby

NIHR ACF PhD studentship subject to successful application:

Adenike Adebayo

Top